CLOTTING FACTORS FROM FISH BLOOD FOR FIBRIN SEALANTS

用于纤维蛋白密封剂的鱼血凝血因子

• 批准号: 6357580
• 负责人: EVELYN SAWYER
• 金额: $ 3.8万
• 依托单位: SEA RUN HOLDINGS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-22 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6357580
• 关键词: animal extract; aquaculture; biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; biotechnology; cell line; clotting factor; dogs; drug design /synthesis /production; drug discovery /isolation; fibrin; fibrinogen; laboratory rabbit; laboratory rat; protein purification; surgery material /equipment; swine; thrombin; trout /salmon

The objective of this project is to create a safe, efficacious surgical fibrin sealant from salmon plasma. Millions of large salmon are reared by the aqua-culture industry, and the plasma from these fish offers an innovative and alternative source of highly conserved clotting factors. A likely health advantage of the salmon material is safety from mammalian infectious agents. Specific aims are; (1) to extract, purify, and evaluate in vitro, thrombin and fibrinogen from the plasma of framed salmon; (2) evaluate the possible risks of trans-species (salmon-human) infectious agents; (3) determine the immunogenic properties of the salmon material; and (4) test the salmon material in vivo in animal models. Salmon thrombin and fibrinogen will be purified, and tested in vitro at varying concentration and conditions. Lots (>1000 fish) of salmon plasma will be screened for salmon virus, and any virus found will e identified and tested for infectivity in human cell lines. Immunogenicity will be evaluated in both rats and rabbits. The in vivo efficacy of a salmon fibrin sealant and a commercial (human-derived" sealant will be compared in rat, dog, and swine models. PROPOSED COMMERCIAL APPLICATIONS: A fibrin sealant derived from salmon plasma could offer safety from mammalian infectious agents, and certain physical-chemical advantages over mammalian material. The U.S. market is over $400 million, in addition to military use.

该项目的目标是从鲑鱼血浆中创造一种安全、有效的外科纤维蛋白密封剂。数以百万计的大型三文鱼是由水产养殖业饲养的，这些鱼的血浆提供了一种高度保守的凝血因子的创新和替代来源。鲑鱼材料的一个可能的健康优势是安全，不受哺乳动物感染性物质的影响。具体目标是：(1)从框架鲑鱼的血浆中提取、纯化和体外评估凝血酶和纤维蛋白原；(2)评估跨物种(鲑鱼-人类)感染剂的可能风险；(3)确定鲑鱼材料的免疫原性；以及(4)在动物模型中测试鲑鱼材料。鲑鱼凝血酶和纤维蛋白原将被提纯，并在不同浓度和条件下进行体外测试。将对大量的鲑鱼血浆(1000条鱼)进行鲑鱼病毒筛查，发现的任何病毒都将被鉴定并在人类细胞系中进行传染性测试。免疫原性将在大鼠和兔身上进行评估。鲑鱼纤维蛋白密封剂和商业(人源性)密封剂的体内有效性将在大鼠、狗和猪的模型中进行比较。拟议的商业应用：从鲑鱼血浆中提取的纤维蛋白密封剂可以提供安全的哺乳动物感染性病原体，以及相对于哺乳动物材料的某些物理化学优势。除军事用途外，美国市场价值超过4亿美元。